These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 2416371)

  • 21. [Clinicopathological study of latent carcinoma--with special reference to prostatic cancer].
    Moriwaki S; Yamamoto Y; Takashima S; Uyama K; Higa I; Kanayama H
    Gan No Rinsho; 1985 Jun; 31(7):847-53. PubMed ID: 2411968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
    Yoshiki T; Okada K; Oishi K; Yoshida O
    Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
    Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
    Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma.
    Myers RB; Srivastava S; Grizzle WE
    J Urol; 1995 May; 153(5):1572-4. PubMed ID: 7714977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
    McNeel DG; Nguyen LD; Ellis WJ; Higano CS; Lange PH; Disis ML
    Prostate; 2001 May; 47(3):222-9. PubMed ID: 11351352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prostate-specific antigen. A new marker of prostatic pathology].
    Boccon-Gibod L; Géraud M; Dugué MA
    Ann Urol (Paris); 1988; 22(3):206-10. PubMed ID: 2456714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prostatic adenocarcinoma showing features of endometrioid and mucinous carcinomas: a case report].
    Nishimura K; Higashino M; Hara T; Oka T
    Hinyokika Kiyo; 1995 Oct; 41(10):805-7. PubMed ID: 8533679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The laboratory diagnosis of prostatic adenocarcinoma.
    Griffiths JC
    Crit Rev Clin Lab Sci; 1983; 19(3):187-204. PubMed ID: 6144453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
    Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
    Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
    Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
    J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical demonstration of tumor-associated antigens in prostatic carcinomas of various histological differentiations.
    Friedmann W; Steffens J; Lobeck H; Blümcke S; Nagel R
    Eur Urol; 1985; 11(1):52-6. PubMed ID: 2580711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical evaluation of a prostate-specific antigen as a serum marker of prostatic cancer].
    Park YC; Kiwamoto H; Nishioka T; Tsujihashi H; Mitsubayashi S; Matsuura T; Akiyama T; Kurita T; Miyamoto T
    Hinyokika Kiyo; 1987 Jun; 33(6):883-8. PubMed ID: 2445188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
    Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
    Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
    Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase.
    Svanholm H
    Acta Pathol Microbiol Immunol Scand A; 1986 Jan; 94(1):7-12. PubMed ID: 2421532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostatic carcinoma metastatic to bone: sensitivity and specificity of prostate-specific antigen and prostatic acid phosphatase in decalcified material.
    Shah NT; Tuttle SE; Strobel SL; Gandhi L
    J Surg Oncol; 1985 Aug; 29(4):265-8. PubMed ID: 2417056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunologic sperm detection].
    Müller V; Hinkelmann G
    Arch Kriminol; 1991; 188(3-4):106-9. PubMed ID: 1722088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Schistosomiasis, metaplasia and squamous cell carcinoma of the prostate: histogenesis of the squamous cancer cells determined by localization of specific markers.
    Al Adnani MS
    Neoplasma; 1985; 32(5):613-22. PubMed ID: 2415839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cytological and immunocytochemical study of prostatic carcinoma cell in voided urine. Usefulness of prostate-specific antigen in cytology specimen].
    Kaneoka A; Kawabe T; Takasu K
    Rinsho Byori; 1990 Nov; 38(11):1295-300. PubMed ID: 1703246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications.
    Epstein JI; Eggleston JC
    Hum Pathol; 1984 Sep; 15(9):853-9. PubMed ID: 6381284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.